SEC Comment Letter for PALVELLA THERAPEUTICS, INC. (PVLA) (CIK 0001583648) (PVLA) — Dec 6, 2013
PALVELLA THERAPEUTICS, INC. (PVLA) (CIK 0001583648)
Date: Dec. 6, 2013 · CIK: 0001583648 · Accession: 0000000000-13-066667
AI Filing Summary & Sentiment
Show Raw Text
December 6, 2013 Via E -mail Aleksandrs Sviks Marika Inc. Chief Executive Officer 2360 C orporate Circle , Suite 400 Henderson, NV 89074 Re: Marika Inc. Amendment No. 2 to Registration Statement on Form S -1 Filed November 21, 2013 File No. 333 -190728 Dear Mr. Sviks: We have reviewed your registration statement and have the following comments. In some of our comments, we may ask you to provide us with information so that we may better understand your disclosure. Please respond to this letter by amending your registration statement and providing the requested information. If you do not believe our comments apply to your facts and circumstances or do not believe an a mendment is appropriate, please tell us why in your response. General 1. We note that you have updated your financials to provide September 30, 2013 results but you have not updated your related prospectus disclosures. For example, on page 4 you have prese nted Selected Financial Data as of June 30, 2013 instead of September 30, 2013. Please review your entire prospectus to ensure that it is update d and provide s the most current information as of the most recent date practicable. Exhibit 23.2 2. We note t hat your auditor consent s to the use of the financial statements of Marika, Inc. as of September 30, 2013 and for the period from inception May 24, 2013 to September 30, 2013, to be included in and made part of any filing to be filed with the U.S. Securities and Exchange Commission. The auditor should consent to the use of the auditor’s opinion as opposed to the financial statements. Please revise. Aleksandrs Sviks Marika Inc. December 6, 2013 Page 2 Please contact Elizabeth Sellars , Staff Accountant , at (202) 551 -3348 or Jason Niethamer, Assistan t Chief Accountant at (202) 551 -3855 if you have any questions regarding comments on the financial statements and related matters. Please contact Scott Anderegg, Staff Attorney , at (202) 551 -3342, or me at (202) 551 -3720 with any other questions. Sincere ly, /s/ Mara L. Ra nsom Mara L. Ransom Assistant Director